List of Epaned drug patents

Epaned is owned by Azurity.

Epaned contains Enalapril Maleate.

Epaned has a total of 9 drug patents out of which 0 drug patents have expired.

Epaned was authorised for market use on 20 September, 2016.

Epaned is available in solution;oral dosage forms.

Epaned can be used as treatment of hypertension; method of treating left ventricular dysfunction; method of treating hypertension; method of treatment of heart failure; treatment of heart failure, method of treatment of heart failure; treatment of heart failure; method of treating hypertension; method of treating left ventricular dysfunction; treatment of hypertension.

The generics of Epaned are possible to be released after 25 March, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173141 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US10039745 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US9808442 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US10154987 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US10786482 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US9669008 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US10772868 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US11040023 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

US11141405 AZURITY Enalapril formulations
Mar, 2036

(13 years from now)

Drugs and Companies using ENALAPRIL MALEATE ingredient

Market Authorisation Date: 20 September, 2016

Treatment: Method of treatment of heart failure; Treatment of heart failure; Method of treating hypertension; Method of treating left ventricular dysfunction; Treatment of hypertension

Dosage: SOLUTION;ORAL

How can I launch a generic of EPANED before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic